Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
R P PerngJ Whang-Peng

Abstract

A phase II randomized study was conducted to evaluate the efficacy and toxicity of gemcitabine (GEM) versus the combination of cisplatin and etoposide (EP) in Chinese patients with inoperable (stage III or IV) non-small-cell lung cancer (NSCLC). From March 1995 to February 1996, 53 patients were enrolled onto the study: 27 onto the GEM arm and 26 onto the EP arm. In the GEM arm, gemcitabine 1,250 mg/m2 was given as a 30-minute intravenous (i.v.) infusion on days 1, 8, and 15 of each 28-day cycle. In the EP arm, cisplatin 80 mg/m2 was given on day 1 and etoposide 80 mg/m2 was given on days 1, 2, and 3 of each 28-day cycle. Twenty-six patients are assessable for treatment response on the GEM arm and 24 on the EP arm. Five patients (19.2%) on the GEM arm and five patients (20.8%) on the EP arm achieved a partial response (PR). No complete responses were attained on either treatment arm. All patients enrolled onto the study were eligible for toxicity assessment. The main toxicities were myelosuppression and vomiting, which included World Health Organization (WHO) grade 3 or 4 leukopenia (3.7%), thrombocytopenia (7.4%), anemia (7.4%), and nausea/vomiting (3.7%) on the GEM arm, and WHO grade 3 or 4 leukopenia (30.8%), thrombocytopeni...Continue Reading

Citations

May 20, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P ComellaG Comella
Dec 21, 2000·Current Oncology Reports·M R RansonN Thatcher
Dec 21, 2000·Current Oncology Reports·C J Langer
Aug 10, 2005·Expert Opinion on Pharmacotherapy·Kerry CheongPeter Harper
Dec 6, 2005·Cancer Chemotherapy and Pharmacology·Frédéric GagnadouxEtienne Lemarié
Nov 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christer SederholmSulochana R Gawande
Mar 16, 2001·Expert Opinion on Pharmacotherapy·I Sekine, N Saijo
Mar 25, 2006·Future Oncology·L ToschiF Cappuzzo
Jun 4, 2008·Journal of Aerosol Medicine and Pulmonary Drug Delivery·Frederic GagnadouxEtienne Lemarie
Apr 20, 2012·The Cochrane Database of Systematic Reviews·Catherine DelbaldoJean Pierre Pignon
Oct 21, 2015·The Cochrane Database of Systematic Reviews·Fábio N SantosRachel Riera
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G FrasciG Comella
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F CardenalR Rosell
Jul 29, 2011·Journal of Aerosol Medicine and Pulmonary Drug Delivery·Etienne LemarieFrederic Gagnadoux
Jun 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E LaackUNKNOWN German and Swiss Lung Cancer Study Group
Mar 3, 2007·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·K Le LayR Launois
Feb 25, 2014·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Eileen MannionDympna Waldron
Jun 1, 2007·Expert Review of Pharmacoeconomics & Outcomes Research·Luca ToschiFederico Cappuzzo
Jun 22, 2005·Journal of Aerosol Medicine : the Official Journal of the International Society for Aerosols in Medicine·Frédéric GagnadouxEtienne Lemarié
Feb 1, 2004·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Jong-Sung ParkHyo-Jin Kim
Jul 6, 2000·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·J P SculierJ Klastersky
Nov 7, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P M FracassoS L Sun

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.